[
  {
    "ts": "2026-01-15T04:13:06+00:00",
    "headline": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
    "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-novo-nordisk-reshapes-its-strategy-under-new-ceo/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "b414eda8-cf17-37cb-b7c9-c6c1464a5b8e",
      "content": {
        "id": "b414eda8-cf17-37cb-b7c9-c6c1464a5b8e",
        "contentType": "STORY",
        "title": "JPM26: Novo Nordisk reshapes its strategy under new CEO",
        "description": "",
        "summary": "Novo is positioning itself as a long‑term leader across multiple obesity segments.",
        "pubDate": "2026-01-15T04:13:06Z",
        "displayTime": "2026-01-15T04:13:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m9hRgcHsaxFnPMapF7dREg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y6HX0lxrpZR4ULhZqw1OVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/60670c97cdd29dc9e4d8e24cd63ac6e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-novo-nordisk-reshapes-its-strategy-under-new-ceo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-novo-nordisk-reshapes-strategy-041306688.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T04:04:58+00:00",
    "headline": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
    "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
    "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-enters-2026-with-strong-momentum-given-pipeline-innovation/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "275e6e24-e9e1-3e83-b111-03bc2891eb1a",
      "content": {
        "id": "275e6e24-e9e1-3e83-b111-03bc2891eb1a",
        "contentType": "STORY",
        "title": "JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation",
        "description": "",
        "summary": "Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.",
        "pubDate": "2026-01-15T04:04:58Z",
        "displayTime": "2026-01-15T04:04:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L91cjHFSZBMXC6h1bBPvVA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ShFiCgASkTfyaCE7q2Kwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/58a9664797f2da0158a6a37793342c15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/analyst-comment/jpm26-eli-lilly-enters-2026-with-strong-momentum-given-pipeline-innovation/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-eli-lilly-enters-2026-040458178.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]